

PAPER PUBLISHED IN PEER-REVIEWED JOURNALS

- 1 Bregni M, Siena S, **Di Nicola M**, Bonadonna G and Gianni AM: Tropisetron plus Haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy.
Eur J Cancer 1991;27 (5): 561-565 **I.F.: 5.536** **C.I.: 20**
- 2 Siena S, Bregni M, Belli N, Ravagnani F, P.Notti, Magni M, **Di Nicola M**, Bonadonna G and Gianni AM: Pratical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantaion in cancer patients.
Int J Cell Cloning 1992; 10: 26-29. **I.F.: 7.781** **C.I.:nd**
- 3 Orazi A, Cattoretti G, Schirò R, Siena S, Bregni M, **Di Nicola M** and Gianni AM: Recombinant human Interleukin-3 and recombinant human Granulocyte-Macrophage Colony-Stimulating factor administered in vivo after high-dose ciclophosphamide cancer teraphy: effect on hematopoiesis and microenvironment in human bone marrow.
Blood 1992; 79: 2610-2619 **I.F.: 9.898** **C.I.: 26**
- 4 Bregni M, Magni M, Siena S, **Di Nicola M**, Bonadonna G and Gianni AM:Human peripheral blood hematopoietic progenitors are optimal targets of retroviral mediated gene transfer.
Blood 1992; 80: 1418-1422 **I.F.: 9.898** **C.I.: 77**
- 5 Gianni AM, Bregni M, Siena S, Magni M, **Di Nicola M**, Lombardi F, Tarella C, Pileri A and Bonadonna G:GM-CSF or G-CSF infusion makes high-dose Etoposide a safe outpatient regimen, that is effective in lymphoma and myeloma patients.
J Clin Oncol 1992; 10: 1955-1962 **I.F.: 18.373** **C.I.: 23**
- 6 Gianni AM, Siena S, Bregni M, **Di Nicola M**, Peccatori F, Magni M, Ravagnani F, Sklenar I and Bonadonna G: Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m²) cyclophosphamide cancer therapy.
Ann Oncol 1993; 4: 759-766 **I.F.: 6.424** **C.I.: 17**
- 7 Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, **Di Nicola M**, Bagnara G, Gianni AM:Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).
Stem Cells 1993; 11: 72-75 **I.F.: 7.781** **C.I.: 5**
- 8 Ravagnani R, Notti P, Siena S, Bregni M, Zorzino L, **Di Nicola M**, Belli N, Gianni AM, Pellegris G: Clinical application of growth factors for collection of circulating hematopoietic progenitors in breast cancer patientes treated with high-dose cyclophosphamide.
Int J Artificial Organ 1993; 16: 80-82 (S-5) **I.F.: 1.861** **C.I.: 3**
- 9 **Di Nicola M**, Siena S, Bregni M, Peccatori F, Ravagnani F, Zorzino L, Bonadonna G, and Gianni AM: Quantization of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients.
Int J Artificial Organ 1993; 16: 35-38 **I.F.: 1.861** **C.I.: 3**
- 10 Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, **Di Nicola M**, Magni M, Peccatori F, Valagussa P, and Bonadonna G: High dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - a 6-year

update.

- Ann Oncol 1993; 4: 889-891 **I.F.: 6.424** **C.I.: 54**
- 11** Siena S, Bregni M, **Di Nicola M**, Ravagani F, Peccatori F, Gandola L, Lombardi F, Tarella C, Bonadonna G, Gianni AM: Durability of hematopoiesis following myeloablative cancer therapy and autografting with circulating hematopoietic progenitors.
Ann Oncol 1994; 5: 935-941 **I.F.: 6.424** **C.I.: 55**
- 12** **Di Nicola M**, Siena S, Bregni M, Ravagnani F, Vitello F, Belli N, Dodero A, Magni M, Bonadonna G, Gianni AM: Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon-wool-adherent mature cells.
Bone Marrow Transpl 1994;14, 863-869 **I.F.: 3.746** **C.I.: 6**
- 13** Siena S, **Di Nicola M**, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G, Gianni AM: Massive ex-vivo generation of functional dendritic cells from mobilized CD34+ peripheral blood progenitors - a protocol suitable for cancer therapy.
Exp Hematol 1995; 23: 1463-1471 **I.F.: 2.905** **C.I.: 216**
- 14** Bregni M, Siena S, **Di Nicola M**, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM: Comparative effects of GM-CSF and G-CSF after high-dose cyclophosphamide cancer therapy.
J Clin Oncol 1996; 14: 628-635 **I.F.: 18.373** **C.I.: 33**
- 15** Siena S, Bregni M, **Di Nicola M**, Magni M, Ravagnani F, Gandola L, Lombardi F, Gianni AM: Ricostituzione ematopoietica a lungo termine dopo terapie antitumorali mieloablativa e trapianto di progenitori ematopoietici circolanti.
Tumori 1996; 2: 23-27 **I.F.: 0.606** **C.I.: nd**
- 16** Tassone P, Turco MC, Tuccillo F, Bonelli P, Morrone G, Cecco L, Cerra M, Bond H, **Di Nicola M**, Gianni AM, Venuta S: CD69 expression on primitive progenitor cells and hematopoietic malignancies.
Tissue Antigens 1996; 48: 65-68 **I.F.: 2.588** **C.I.: 2**
- 17** **Di Nicola M**, Bregni M, Siena S, Ruffini PA, Milanese M, Ravagnani F, Gianni AM: Combined negative and positive selection of peripheral blood mobilized CD34+ cell transplants.
Brit J Haematol 1996; 94: 716-721 **I.F.: 4.941** **C.I.: 17**
- 18** **Di Nicola M**, Siena S, Bregni M, Belli N, Milanese M, Ruffini PA, Malaffo F, Ravagnani F, Gianni AM: Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute.
Bone Marrow Transp 1996; 18: 619-623 **I.F.: 3.746** **C.I.: 8**
- 19** **Di Nicola M**, Siena S, Corradini P, Bregni M, Milanese M, Magni M, Ruffini PA, Ravagnani F, Tarella C, Gianni AM: Elimination of *bcl-2*-IgH-positive follicular lymphoma cells from blood cell transplants with high recovery of hematopoietic progenitor cells by the Miltenyi CD34+ cell sorting system.
Bone Marrow Transp 1996; 18: 1117-1121 **I.F.: 3.746** **C.I.: 25**
- 20** Gianni AM, Bregni M, Siena S, Brambilla C, **Di Nicola M**, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G: Comparison of high-dose sequential therapy versus MACOP-B in patients with poor prognosis large B-cell lymphoma.

- N Engl J Med 1997; 336: 1290-1297 **I.F.: 53.298 C.I.: 406**
- 21 Gianni AM, Siena S, Bregni M, **Di Nicola M**, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G: Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more axillary nodes involved - five-years results.
J Clin Oncol 1997;15: 2312-2321 **I.F.: 18.373 C.I.: 155**
- 22 Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, **Di Nicola M**, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB: Inhibition of ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
Blood Cells, Mol, and Dis 1997; 23: 380-394 **I.F.: 2.427 C.I.: 241**
- 23 Mortarini R, Anichini A, **Di Nicola M**, Siena S, Bregni M, Belli F, Molla A, Gianni AM, Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and monocytes are not functionally equivalent APC induction of Melan-A/Mart-27-35-specific CTL from PBL of melanoma patients with low frequency of CTL precursors.
Cancer Res 1997; 57: 5534-5541 **I.F.: 7.856 C.I.: 103**
- 24 Bregni M, **Di Nicola M**, Siena S, Belli N, Milanese M, Shammah S, Ravagnani F, Gianni AM: Mobilized peripheral blood CD34+ cells express more amphotropic retrovirus receptor than bone marrow CD34+ cells.
Haematologica 1998; 83: 204-208 **I.F.: 6.424 C.I.: 7**
- 25 Bregni M, Shammah S, Malaffo F, **Di Nicola M**, Milanese M, Magni M, Matteucci P, Ravagnani F, Jordan CT, Siena S, Gianni AM: Adenovirus vectors for gene transduction into mobilized blood CD34+ cells.
Gene Therapy 1998; 5: 465-472 **I.F.: 3.710 C.I.: 36**
- 26 Chiti A, **Di Nicola M**, Spinelli A, Siena S, Bregni M, Savelli G, Gianni MA, Bombardieri E: A case of metastatic axillary lymph nodes involvement from unknown primary cancer: clinical usefulness of (99mTc)-sestamibi.
Tumori 1998;84: 612-613 **I.F.: 0.606 C.I.: 2**
- 27 **Di Nicola M**, Siena S, Bregni M, Longoni P, Magni M, Milanese M, Matteucci P, Mortarini R, Anichini A, Parmiani G, Drexler I, Erfle V, Sutter G, Gianni AM: Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.
Cancer Gene Therapy 1998;5:350-356 **I.F.: 2.802 C.I.: 54**
- 28 Ravagnani F, Siena S, De Reys S, **Di Nicola M**, Notti P, Giardini R, Bregni M, Matteucci P, Gianni AM, Pellegris G: Improved collection of mobilized CD34+ hematopoietic progenitors for blood cell transplantation by a novel COBE Spectra automated leukapheresis system.
Transfusion 1999; 39:48-55 **I.F.: 3.217 C.I.: 32**
- 29 **Di Nicola M**, Longoni P, Magni M, Gianni AM: The influence of interleukin (IL)-4 and IL-13 on human dendritic cell differentiation from CD34+ progenitor cells: the importance of the source of serum.
Exp Hematol 27: 386-388, 1999 **I.F.: 2.905 C.I.: 2**
- 30 **Di Nicola M**, Milanese M, Magni M, Bregni M, Carlo-Stella C, Longoni P, Tomanin R,

- Ravagnani F, Scarpa M, Jordan C, Gianni AM: Recombinant adenoviral vector-lipofectamine complex for gene transduction into human T-lymphocytes.
Human Gene Therapy 1999; 10:1875-1884 **I.F.: 4.218 C.I.: 13**
- 31 Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, **Di Nicola M**, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G: An expanded peripheral T cell population to a CTL-defined melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTL, but does not overcome tumor escape from immune surveillance in metastatic lesions.
J Exp Med 1999; 190:651-668 **I.F.: 13.853 C.I.: 146**
- 31 Magni M*, **Di Nicola M***, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM: Successful in vivo purging of CD34 containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
Blood 2000;96:864-869 **I.F.: 9.898 C.I.: 196**
*Equally contributed
- 32 **Di Nicola M**, Carlo-Stella C, Milanese M, Magni M, Longoni P, Mortarini R, Anichini A, Tomanin R, Scarpa M, Gianni AM: Large-scale feasibility of gene transduction into human CD34+ derived-dendritic cells by adenoviral/polycation complex.
Br J Haematol 2000;111: 344-50 **I.F.: 4.914 C.I.: 16**
- 33 Bonfante V, Viviani S, Devizzi L, Di Russo A, **Di Nicola M**, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM: High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
Eur J Haematol 2001; 66 (Suppl. 64): 51-55 **I.F.: 2.614 C.I.: 14**
- 34 Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, Tarella C, Zaglio F, Vitolo U, **Di Nicola M**, Pogliani E, Cavalli F, Gianni AM, Barbui T: Intensification of salvage treatment with high dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Br J Haematol. 2001;114:333-41 **I.F.: 4.914 C.I.: 25**
- 35 **Di Nicola M**, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
Blood 2002;99:3838-43 **I.F.: 9.898 C.I.: 1050**
- 36 Matteucci P, Magni M, **Di Nicola M**, Carlo-Stella C, Uberti C, Gianni AM: Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.
Blood 2002;100:1104-5 **I.F.: 9.898 C.I.: 49**
- 37 Carlo-Stella C, **Di Nicola M**, Magni M, Longoni P, Milanese M, Stucchi C, Cleris L, Formelli F, Gianni MA: Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.
Cancer Res. 2002;62:6152-7 **I.F.: 7.856 C.I.: 11**
- 38 Tarella C, **Di Nicola M**, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M,

- Matteucci P, Gallamini A, Pileri A, Gianni AM: High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Bone Marrow Transplant. 2002;30:725-32 **I.F.: 3.746 C.I.: 27**
- 39 Magni M, **Di Nicola M**, Carlo-Stella C, Matteucci P, Lavazza C, Grisanti S, Bifulco C, Pilotti S, Papini D, Rosai J, Gianni AM: Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor.
Leuk Res. 2002;26:1131-3 **I.F.: 2.923 C.I.: 14**
- 40 Gianni AM, Magni M, Martelli M, **Di Nicola M**, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Blood 2003;102:749-55 **I.F.: 9.898 C.I.: 126**
- 41 Tarella C, Cuttica A, Vitolo U, Liberati M, **Di Nicola M**, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A: High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Cancer 2003;97:2748-59 **I.F.: 4.771 C.I.: 50**
- 42 Cuttica A, Zallio F, Ladetto M, **Di Nicola M**, Caracciolo D, Magni M, Marinone C, Dell'Aquila M, Rosace M, Pileri A, Boccadoro M, Gianni AM, Tarella C: Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.
Cancer 2003;98:983-92 **I.F.: 4.771 C.I.: 11**
- 43 **Di Nicola M**, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, Ravagnani F, Morelli D, Chaplin P, Arndtz N, Sutter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM: Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Hum Gene Ther 2003;14:1347-60 **I.F.: 4.218 C.I.: 18**
- 44 **Di Nicola M**, Napoli S, Anichini A, Mortarini R, Romagnoli L, Magni M, Matteucci P, Baldassarri P, Bersani I, Carlo-Stella C, Gianni AM: Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.
Haematologica 2003;88:1396-404 **I.F.: 6.424 C.I.: 8**
- 45 C.Carlo-Stella, **M.Di Nicola**, P.Longoni, R.Milani, M.Milanesi, A.Guidetti, K.Haanstra, M.Jonker, L.Cleris, M.Magni, F.Formelli, AM.Gianni: Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.
Exp Hematol 2004;32:68-75 **I.F.: 2.905 C.I.: 5**
- 46 H.M.Bond, M.Mesuraca, E.Carbone, P.Bonelli, V.Agosti, N.Amodio, G.De Rosa, **M.Di**

- Nicola**, AM.Gianni, MA.Moore, A.Hata, M.Grieco, G.Morrone, S.Venuta: Early hematopoietic zinc finger protein (EHZF), the human homologue to mouse Evi3, is highly expressed in primitive human hematopoietic cells.
Blood 2004; 103:2062-70 **I.F.: 9.898 C.I.: 39**
- 47 C.Carlo-Stella, **M.Di Nicola**, R.Milani, A.Guidetti, M.Magni, M.Milanesi, P.Longoni, P.Matteucci, F.Formelli, F.Ravagnani, P.Corradini, AM.Gianni: Use of Recombinant Human Growth Hormone (rhGH) plus Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) for the Mobilization and Collection of CD34+ Cells in Poor Mobilizers.
Blood 2004; 103:3287-95 **I.F.: 9.898 C.I.: 24**
- 48 C.Carlo-Stella, **M.Di Nicola**, R.Milani, P.Longoni, M.Milanesi, C.Bifulco, C.Stucchi, A.Guidetti, L.Cleris, F.Formelli, G.Garotta, A.M.Gianni: Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone.
Exp Hematol 2004;32:171-178 **I.F.: 2.905 C.I.: 20**
- 49 **M.Di Nicola**, C.Carlo-Stella, J.Mariotti, L.Devizzi, M.Massimino, A.Cabras, M.Magni, P.Matteucci, A.Guidetti, L.Gandola, A.M. Gianni: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
Br J Haematol 2004, 126:815-20 **I.F.: 4.941 C.I.: 15**
- 50 **M.Di Nicola**, C.Carlo-Stella, R.Mortarini, P.Baldassari, A.Guidetti, F.Gallino, M.Del Vecchio, F.Ravagnani, M.Magni, P.Chaplin, N.Cascinelli, G.Parmiani, A.M. Gianni, and A.Anichini: Boosting T Cell-Mediated Immunity To Tyrosinase By Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. A Phase I Trial In Metastatic Melanoma.
Clin Cancer Res 2004, 10:5381-90 **I.F.: 7.742 C.I.: 45**
- 51 A.Anichini, R.Mortarini, L.Romagnoli, P.Baldassari, A.Cabras, C.Carlo-Stella, A.M.Gianni, **M.Di Nicola**: Skewed T cell differentiation in indolent non-Hodgkin's lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines.
Blood 2005 Sep 8; [Epub ahead of print] **I.F.: 9.898 C.I.: 8**
- 52 P.Matteucci, C.Carlo-Stella, **M.Di Nicola**, M.Magni, A.Guidetti, M.Marchesi, A.M.Gianni: Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.
Haematologica 2006; 91:255-7 **I.F.: 6.424 C.I.: 5**
- 53 C.Carlo-Stella, **M.Di Nicola**, M.C.Turco, L.Cleris, C.Lavazza, P.Longoni, M.Milanesi, M.Magni, M.Ammirante, A.Leone, Z.Nagy, W.R.Gioffre, F.Formelli, A.M.Gianni: The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
Cancer Res 2006; 66:1799-808 **I.F.: 7.856 C.I.: 23**
- 54 L.Passoni, B.Gallo, E.Biganzoli, R.Stefanoni, M.Massimino, **M.Di Nicola**, A.M.Gianni, C.Gambacorti-Passerini: In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas.
Haematologica 2006; 91:48-55 **I.F.: 6.424 C.I.: 12**
- 55 C.Carlo-Stella, A.Guidetti, **M.Di Nicola**, P.Longoni, L.Cleris, C.Lavazza, M.Milanesi, R.Milani, M.Carrabba, L.Farina, F.Formelli, A.M.Gianni, P.Corradini: CD52 antigen expressed by

- malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Exp Hematol 2006 Jun;34(6):721-7 I.F.: 2.905 C.I.: 6
- 56 C.Carlo-Stella, C.Lavazza, **M.Di Nicola**, L.Cleris, P.Longoni, M.Milanesi, M.Magni, D.Morelli, A.Gloghini, A.Carbone, A.M.Gianni: Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.
Hum Gene Ther 2006 Dec;17(12):1225-40 I.F.: 4.218 C.I.: 17
- 57 V.Perfetti, S.Siena, G.Palladini, M.Bregni, **M.Di Nicola**, L.Obici, M.Magni, L.Brunetti, A.M.Gianni, G.Merlini: Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Haematologica 2006 Dec;91(12):1635-43 I.F.: 6.424 C.I.: 25
- 58 C.Carlo-Stella, **M.Di Nicola**, P.Longoni, L.Cleris, C.Lavazza, R.Milani, M.Milanesi, M.Magni, V.Pace, F.Colotta, M.A.Avanzini, F.Formelli, A.M.Gianni: Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates.
Stem Cells 2007 Jan;25:252-61 I.F.: 7.781 C.I.: 7
- 59 SP.Perrine, O.Hermine, T.Small, F.Suarez, R.O'Reilly, F.Boulad, J.Fingerroth, M.Askin, A.Levy, S.J.Mentzer, **M.Di Nicola**, A.M.Gianni, C.Klein, S.Horwitz, D.V.Faller: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.
Blood 2007 Mar 15;109(6):2571-8 I.F.: 9.898 C.I.: 72
- 60 C.Carlo-Stella, A.Guidetti, **M.Di Nicola**, C.Lavazza, L.Cleris, D.Sia, P.Longoni, M.Milanesi, M.Magni, Z.Nagy, P.Corradini, A.Carbone, F.Formelli, A.M.Gianni: IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Cancer Res 2007 Apr 1;67(7):3269-75 I.F.: 7.856 C.I.: 6
- 61 C Tarella, M Zanni, **M Di Nicola**, C Patti, R Calvi, A Pescarollo, V Zoli, A Fornari, D Novero, A Cabras, M Stella, A Comino, D Remotti, M Ponzoni, D Caracciolo, M Ladetto, M Magni, L Devizzi, R Rosato, M Boccadoro, M Bregni, P Corradini, A Gallamini, I Majolino, S Mirto and AM Gianni, on behalf of the Gruppo Italiano Terapie Innovative nei Linfomi (GITIL): Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
Leukemia. 2007 Aug;21(8):1802-11. Epub 2007 Jun 7. I.F. 9.561 C.I.:29
- 62 C Lavazza, C Carlo-Stella, **M Di Nicola**, P Longoni, M Milanesi, M Magni, AM Gianni: Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent.
Exp Hematol. 2007 Jun;35(6):888-97. I.F. 2.905 C.I.:2
- 63 Zappasodi R, **Di Nicola M***, Carlo-Stella C, Mortarini R, Molla A, Vegetti C, Albani S, Anichini A, Gianni AM: The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Haematologica. 2008 Oct;93(10):1523-34. Epub 2008 Aug 25. I.F.: 6.424 C.I.:10

*Corresponding Author

- 64 **Di Nicola M**, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2009 Jan 1;113(1):18-27. Epub 2008 Sep 22. **I.F.: 9.898 C.I.:22**
- 65 Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, **Di Nicola M**, Carlo-Stella C, Gianni AM. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol. 2008 Nov 10;26(32):5175-82. Epub 2008 Oct 14. **I.F.: 18.372 C.I.:32**
- 66 Magni M, **Di Nicola M**, Carlo-Stella C, Matteucci P, Devizzi L, Tarella C, Benedetti F, Martelli M, Patti C, Parvis G, Rambaldi A, Barbui T, Gianni AM. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant. 2009 Mar;43(6):509-11. Epub 2008 Oct 27 **I.F.: 3.746 C.I. 11**
- 67 Magni M, **Di Nicola M**, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM. Radioimmunotherapy and secondary leukemia: a case report. Leuk Res. 2010 Jan;34(1):e1-4. Epub 2009 May 15. **I.F.: 2.923 C.I. 1**
- 68 Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, **Di Nicola M***, Luksch R*. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009 Sep 15;69(18):7338-46. Epub 2009 Sep 1. **I.F.: 7.856 C.I. 34**
* Equally contributed
- 69 Magni M, **Di Nicola M**, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P, Gianni AM. Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplant. 2010;45:1119-20. Epub 2009 Oct 12. **I.F.: 3.746 C.I. 2**
- 70 Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, Sia D, **Di Nicola M**, Magni M, Longoni P, Milanesi M, Francolini M, Gloghini A, Carbone A, Formelli F, Gianni AM. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood. 2010;115:2231-40. Epub 2010 Jan 14. **I.F.: 9.898 C.I. 6**
- 71 Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. Cancer Immunol Immunother. 2010;59:963-9. Epub 2009 Mar 28. **I.F.: 3.701**
- 72 Viviani S*, **Di Nicola M***, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM. Long-term results of high-dose chemotherapy with autologous bone

marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.

Leuk Lymphoma. 2010;51:1251-9. **I.F.: 2.492 C.I. 5**

* Equally contributed

- 73 Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, Colombo MP, Carlo-Stella C, Gianni AM, **Di Nicola M**. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Cancer Res. 2010 Nov 15;70(22):9062-72. Epub 2010 Sep 30. **I.F.: 7.856 C.I. 8**

- 74 Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, **Di Nicola M***, Mortarini R*.
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Cancer Res. 2010 Nov 1;70(21):8378-87. Epub 2010 Sep 21. **I.F.: 7.856 C.I. 6**

* Equally contributed

- 75 Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT.

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009. Cancer Immunol Immunother. 2010;59:1895-901

- 76 Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, **Di Nicola M**, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

J Clin Oncol. 2011 Mar 1;29(7):814-24. Epub 2010 Dec 28. **I.F.: 18.372 C.I. 16**

- 77 Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, **Di Nicola M**, Passera R, Tarella C, Gianni AM. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Cancer. 2011;117:5074-84

I.F.: 4.771 C.I. 1

- 78 Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, **Di Nicola M**. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Blood. 2011;118:4421-30 [Epub ahead of print] **I.F.: 9.898 C.I.**

- 79 Magni M, **Di Nicola M**, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM. Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

Am J Blood Res. 2012;2:105-12.

- 80 Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Doderò A, Tarella C, **Di Nicola M**, Corradini P, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Br J Haematol. 2012;158:108-19

I.F. 4.941

- 81 Ferreri AJ, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, Mappa S, Govi S, **Di Nicola M**, Rossi G, Tirelli U, Caligaris-Cappio F, Spina M, Re A. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Br J Haematol. 2012;159:252-5. **I.F. 4.941**
- 82 Longoni P, Milanese M, **Di Nicola M**, Devizzi L, Carrabba M, Arienti F, Ravagnani F, Tarella C, Montefusco V, Gianni A, Corradini P, Magni M. Successful second autologous engraftment after long duration storage of hematopoietic stem cells.
Bone Marrow Transplant. 2013 Nov;48(11):1480-1 **I.F.: 3.746**
- 83 Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, **Di Nicola M**, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
J Clin Oncol. 2013 Aug 10;31(23):2974-6 **I.F.: 18.372**
- 84 Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, **Di Nicola M**, Farè E, Raggi D, Magni M, Matteucci P, Longoni P, Milanese M, Paternò E, Ravagnani F, Arienti F, Nicolai N, Salvioni R, Carlo-Stella C, Gianni AM. Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Clin Genitourin Cancer. 2014 Jun;12(3):196-202
- 85 Magni M, **Di Nicola M**, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM.
Bone Marrow Transplant. 2014 Apr;49(4):485-91 **I.F.: 3.746**
- 86 Zappasodi R, Cavanè A, Iorio MV, Tortoreto M, Guarnotta C, Ruggiero G, Piovan C, Magni M, Zaffaroni N, Tagliabue E, Croce CM, Zunino F, Gianni AM, **Di Nicola M**. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Int J Cancer. 2014 Mar 20 **I.F.: 6.198**
- 87 Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, **Di Nicola M**. Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Future Oncol. 2014 Jun 20:1-10 **I.F.: 3.202**
- 88 Silvestri I, Testa F, Zappasodi R, Cairo CW, Zhang Y, Lapo B, Galli R, **Di Nicola M**, Venerando B, Tringali C. Sialidase neu4 is involved in glioblastoma stem cells survival.
Cell Death and Disease 2014 (in press). **I.F.: 5.177**
- 89 Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Doderò A, Farina L, Giordano L, **Di Nicola M**, Anichini A, Corradini P, Gianni AM. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Clin Cancer Res. 2014 Nov 15;20(22):5641-51

- 90 Necchi A, Mariani L, **Di Nicola M**, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, BIASONI D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Ann Oncol. 2015 Jan;26(1):167-72
- 91 Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavanè A, Cabras AD, Castagnoli L, Venerando B, Zaffaroni N, Gianni AM, De Braud F, Tripodo C, Pupa SM, **Di Nicola M**. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.
Blood. 2015 Mar 12;125(11):1768-71
*** con Editoriale**
- 92 Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, BIASONI D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, **Di Nicola M**, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Urol Oncol. 2015 Jul;33(7):332.e19-24.
- 93 Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, **Di Nicola M**, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
J Clin Oncol. 2015 Aug 17.
- 94 Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, **Di Nicola M**, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol. 2015 Oct 12.
- 95 Indini A, **Di Nicola M**, Del Vecchio M, De Braud F. Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
J Clin Oncol. 2016 Jan 19
- 96 Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, **Di Nicola M**, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Am J Hematol. 2016 May;91(5):E293-5
- 97 Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, **Di Nicola M**, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Int J Radiat Oncol Biol Phys. 2016;9:783-91

- 98 Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, **Di Nicola M**, Salvioni R, de Braud F, Procopio G. Immunotherapy advances in uro-genital malignancies. *Crit Rev Oncol Hematol* 2016 Sep;105:52-64
- 99 Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, **Di Nicola M**, Patti C, Mule' A, Zanni M, Zoli V, Billio A, Castellino C, Di Raimondo F, Ferreri A, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Masciulli A, Delaini F, Boschini C, And Rambaldi A. Randomized Trial comparing R-CHOP versus High Dose Sequential chemotherapy in High Risk Patients with Diffuse Large B-Cell Lymphomas. *J Clin Oncol*. 2016;34:4015-4022
- 100 Russo V, Amadori A, Bregni M, Calabrò L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M.: Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). *Cytokine Growth Factor Rev*. 2017 Jun 16. [Epub ahead of print]
- 101 Rossini A, et al Di Nicola M: Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. *Hematological Oncology* 2017 (In press).

EDITORIALS AND REVIEWS PUBLISHED PEER-REVIEWED JOURNALS

1. Gianni AM, Bregni M, Siena S, Tarella C, **Di Nicola M** and Bonadonna G: Impiego clinico dei fattori di crescita emopoietici.
Haematologica 1991; 76 (3): 3-10 **I.F.: 6.424** **C.I.: nd**
2. **Di Nicola M**, Bregni M, Siena S, Gianni AM: Fattori di crescita ematopoietici in oncologia medica. in *Progressi in Oncologia Medica* 1993; 4, (suppl. 1), 147-163
3. Siena S, **Di Nicola M**, Bregni M, Mortarini R, Shammah S, Magni M, Matteucci P, Anichini A, Parmiani G, and Gianni AM: Dendritic cells from peripheral blood CD34+ progenitors in cancer patients treated with high dose sequential therapy.
Cancer Forum 1996; 20: 264-267
4. Siena S, **Di Nicola M**, Mortarini R, Anichini A, Bregni M, Parmiani G, and Gianni AM: Expansion of immunostimulatory dendritic cells from peripheral blood of patients with cancer.
The Oncologist 1997; 2: 65-69 **I.F.: 6.701** **C.I. 5**
5. **Di Nicola M**, Anichini A, Mortarini R, Bregni M, Parmiani G, and Gianni AM: Human dendritic cells: natural adjuvants for anticancer immunotherapy.
Cytok Cellular and Mol Ther 1998; 4: 265-273 **C.I.: 20**
6. **Di Nicola M**, Lemoli RM: Dendritic cells: specialized antigen presenting cells.
Haematologica 2000; 85:202-207 **I.F.: 6.424** **C.I.: 17**
7. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, **Di Nicola M**, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S: Antitumor vaccination: where we stand.
Haematologica 2000; 85:1172-1206 **I.F.: 6.424** **C.I.: 57**

8. P.A.Ruffini, **M.Di Nicola**, C.Carlo-Stella, S.Siena, A.M.Gianni: Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
Curr Gene Ther 2005 Oct;5(5):511-21 **I.F.: 3.386 C.I. 4**

9. Zappasodi R, de Braud F, **Di Nicola M**. Lymphoma Immunotherapy: Current Status.
Front Immunol. 2015 Sep 1;6:448

BOOK CHAPTERS

1. Siena S, Bregni M, **Di Nicola M**, Peccatori F, Magni M, Ravagnani F, Brando B, and Gianni AM: Milan protocol for clinical CD34+ cell estimation in peripheral blood for autografting in patients with cancer.
In "Hematopoietic Stem Cells The Mulhouse Manual" AlphaMed Press, 23-30, 1994
2. Siena S, Bregni M, **Di Nicola M**, Doderò A, Bonadonna G, and Gianni AM: Cytokines and peripheral blood hematopoietic progenitors as a therapeutic tool in the treatment of the cancer. in "Progressi in Ematologia clinica", 13, 177-183, 1994
3. Bregni M, Siena S, Magni M, **Di Nicola M**, Ravagnani F, and Gianni AM: Rationale and methods for retroviral-mediated gene transfer into peripheral blood hematopoietic progenitors.
In "Hematopoietic Stem Cells: Biology and Therapeutic Applications", Levitt DJ, Mertelsmann R, Marcel Dekker, (Publ.), New York, 185-194, 1995.
4. Bregni M, Siena S, **Di Nicola M**, Magni M, Malaffo F, Milanese M, and Gianni AM: Trasferimento genico in cellule staminali ematopoietiche umane.
Aggiornamenti in Ematologia clinica 109-110, 1997.
5. **Di Nicola M**, Anichini A, Gianni AM: Terapia genica: dati clinici.
In "Oncologia genetica", D. Amadori e S. Grilli, Poletto Editore, Milano, 255-281, 2001.
6. Parmiani G, **Di Nicola M**, Rivoltini L: Immunologia dei Tumori.
In "Manuale di Oncologia Medica", G.Bonadonna e G.Robustelli Della Cuna, Masson Editore, 2003
7. Parmiani G, **Di Nicola M**, Rivoltini L: Immunologia dei Tumori.
In "Manuale di Oncologia Medica", G:Bonadonna e G.Robustelli Della Cuna, Masson Editore, 2007
8. Zappasodi R, Di Nicola M: Non-Hodgkin's Lymphomas. in Biotargets of Cancer in Current Clinical Practice, Mauro Bologna Editor, Humana Press, 2012
9. Zappasodi R, Filippazzi P, Rivoltini L, **Di Nicola M**: Cancer Vaccines and Active Immunotherapy. in "Non-Hodgkin's lymphoma", www.futuremedicine.com